Pharma IQ to organize Anti-Infectives Summit in Philadelphia

Organized by Pharma IQ, a division of IQPC, the Anti-Infectives Summit will be held January 25-27, 2010 in Philadelphia, PA. This forum explores recent advances within anti-infective drug discovery and development, and is geared towards Chief Scientific Officers and Scientists working in microbiology, immunology, infectious diseases, medicinal chemistry and drug development.

Combating drug resistant strains of viruses and bacteria has created significant challenges for the pharmaceutical and biotech industries. As the demand for new therapies increases, the Anti-Infectives Summit aims to promote a more integrated approach to improving pipelines.

“What is really driving antibiotic discovery and research is real medical need created by the obsolescence of the older classes of antibiotics due to increasing resistance and/or adverse effects,” states Nachum Kaplan, PhD, Vice President, Microbiology, Affinium Pharmaceuticals and a featured speaker at the Summit.

The Anti-Infectives Summit showcases effective lead generation approaches being used in anti-bacterial, anti-viral and anti-fungal drug discovery, including case studies on:

• Targeting superbugs: New, effective Bicyclolides against MRSA and VRE
• A novel regimen for the treatment of TB
• Sustained release of nitric oxide from hybrid nanoparticle platforms
• Emerging market countries and infectious disease needs
• Multi-Drug Resistant Gram-Negative Bacteria challenges and solutions
• Anti-infective drug discovery through outsourcing and collaborations

Dr. Kaplan will present a session titled Bacterial Fatty Acid Synthesis as a Target for AFN-1252: A Novel and Selective-Spectrum Antibiotic for the Treatment of Staphylococcal Infections on Wednesday, January 27, 2010.

Other speakers at the Anti-Infectives Summit include the GlaxoSmithKline, MethylGene Inc, Albert Einstein College of Medicine, Astellas Pharma US, Centers for Disease Control and Prevention, Novartis Institute for Biomedical Research, Pfizer and AstraZeneca.

http://www.iqpc.com/